Kornimate/medical-research-clean huggingface dataset:
robot-assisted or laparoscopic resection for gastric subepithelial tumor with hand-sewn repair, a case series

Conditions: Gastric Mass

Summary: there are a lot of surgical techniques in minimally-invasive surgery to remove gastric subepithelium tumor. surgical approach depend on location and size of tumor. usefully used endostapler to cut stomach include lesion. for tumors in difficult locations some surgeons prefer laparoscopic and endoscopic cooperation or use the intragastric port technique to identify and remove the mass. but in complex procedures, gastotomy and hand sawn to identify and remove gastric subepithelium tumor is a simple technique and easy to apply. this study demonstrates the safety and effectiveness of this technique.

: a retrospective chart review was made of all patients who presented with gastric subepithelial tumor and underwent laparoscopic or robotic resection at ramathibodi hospital during 2012-2018. surgical outcomes and complication of gastotomy and hand-sewn repair were analyzed.

Eligibility criteria:
inclusion criteria: * all patients who presented with gastric subepithelial tumor and underwent laparoscopic or robotic resection at ramathibodi hospital during 2012-2018. exclusion criteria: * conversion to open surgery
motor function assessment system based on video tracking and artificial intelligence technique

Conditions: Cervical Spine Myelopathy

Summary: the goal of this clinical trial is to develop a motion recognition system based on video tracking technology and combine it with artificial intelligence technology to form a motion recognition and function evaluation system in in healthy people and patients with cervical spondylotic myelopathy. the main questions it aims to answer are: * the development of this motion recognition system, * in the scenario of hand motor dysfunction, the key parameters of hand movement in healthy people and patients with cervical spondylotic myelopathy were evaluated, and the hand motor function model was established to achieve an objective, highly sensitive, highly specific, repeatable and easy-to-use system in clinical hand motor function evaluation. participants will recieved the evaluation of this system and mjoa before the surgery. if there is a comparison group: researchers will compare the evaluation results of healthy people to see if this system could recognized the hand motor dysfunction of patients with cervical spondylotic myelopathy.


Eligibility criteria:
inclusion criteria: * study group: 1. patients with cervical spondylotic myelopathy diagnosed by clinical symptoms and cervical spine imaging examination (including cervical flexion and extension x-ray, cervical spine ct and cervical spine mri). * control group: 1. healthy people without clinical and imaging manifestations of cervical spondylotic myelopathy. * age 18-80 years old. * can complete the informed consent process. exclusion criteria: * patients with hand dysfunction caused by other reasons (such as rheumatoid arthritis, history of hand trauma, history of hand surgery, etc.). * patients who cannot complete the assessment process due to various reasons.

Keywords: cervical spine myelopathy hand motor funciton video tracking technology artificial intelligence
microbiota and metabolomics of intestinal type of gastric cancer

Conditions: Gastric Cancer

Summary: compare with the gastric cavity without cancerous transformation in atrophic gastritis, analyze the microbiota and metabolomics changes in intestinal type of gastric cancer under the background of atrophic gastritis, and explore the relevant mechanisms.

this study adopts a prospective cohort study. the expected recruitment time for all participants is 6 months, and all cases are cases who would receive magnifying endoscopy examination. the extent of atrophy and the presence of early gastric cancer are determined under magnifying endoscopy. cases are chose into the gastric cancer group and atrophic gastritis group in a 1:1 ratio. there are 16 cases of intestinal type of gastric cancer under the background of atrophic gastritis, and 16 cases of atrophic gastritis without gastric cancer matched according to gender, age, and degree of gastric atrophy, totaling 32 cases. analyze the characteristics of early gastric cancer under endoscopy, investigate the changes in microbiota and metabolomics of intestinal type of gastric cancer under the background of atrophic gastritis, and explore the relevant mechanisms.

Eligibility criteria:
inclusion criteria: * •intestinal type of gastric cancer or atrophic gastritis * underwent endoscopic submucosal dissection（esd） exclusion criteria: * • have simultaneously other cancer * have severe systemic inflammatory disease ,serious illness such as diabetes, chronic lung diseases
prevalence of fatigue in hemodialysis patients

Conditions: Hemodialysis Patients

Summary: the prevalence of end stage renal disease in taiwan was listed first all over the world. fatigue, which makes patients unable to be competitive to play their functional roles, is one of the most bothersome symptoms of patients receiving long-term hemodialysis. tracing back to the development of its relating studies, there is no accurate reason that why does people undergoing hemodialysis feel fatigued. conclusive predictors of fatigue are still not shown up yet. paper review indicated that the level of l-carnitine concentration, which affect metabolism of fatty acid, had correlation with fatigue and muscle strength in this population. the serum concentration of l-carnitine is influenced a lot by hemodialysis. when there is deficiency of energy supply, it resulted to decline of muscle strength, which increased frequency and intensity of fatigue. hence, the purposes of this study are (1) to understand the basic condition of fatigue level, muscle and metabolism of fat and carbohydrate among hemodialysis patients, (2) to analyze correlation among muscle strength, metabolism of fat/carbohydrate, and fatigue, and (3) to understand correlations among demographic characteristics, blood test data (hemoglobin, albumin, kt/v, urea reduction ratio(urr), blood urea nitrogen(bun), creatinine, calcium, phosphorus, and c-reactive protein), mental and social conditions (depression, anxiety, and social support), muscle strength and fatigue, seeking further exploring predictors of muscle strength and fatigue. the study use cross-sectional descriptive correlative design with consecutive sampling. recruit patients from a hemodialysis unit in a medical center in north taiwan after informed- consent. the estimated sample size is 100. to understand relationship among muscle strength, by-products of fatty acid and carbohydrate and fatigue, we collect data by measuring their muscle strength (handgrip and 30 seconds sit-to-stand), and analyzing blood test data and the structured questionnaires which included mental/social data (depression, anxiety, social support and fatigue level). descriptive statistics, anova, pearson's correlation, spearsman's rank correlation and stepwise regression were used to analyze the collected data. hope this research can get advance in comprehension of cause of fatigue and improve the fatigue symptom of hemodialysis patients.


Eligibility criteria:
inclusion criteria: * 1.hemodialysis patients 2.aged above 20 3.consciousness: oriented exclusion criteria: * 1. unable to complete muscle strength test or questionnaire

Keywords: hemodialysis fatigue muscle strength metabolomics
body composition in older adults

Conditions: Sarcopenia in Elderly; Cachexia; Cancer; Sarcopenia; Body Composition Changes; Older Adults; Nutrition

Summary: the primary aim of the study is to explore body composition in older adults (aged 70 years and over) with cancer, undergoing systemic anticancer treatment. additional aims include to explore the extent of body composition changes and whether changes are tumour specific, the incidence for cancer-related cachexia and sarcopenia and finally, how body composition can inform nutritional management of older adults with cancer. to do this, the investigators applied for and were awarded funding from a company called nutricia to pay for a band 4 (0.6 wte for 7 months) to take monthly body composition measures on the patients who are eligible, accepting of assessment by the senior adult oncology programme (saop) and consent to these measures. measurements will include an analysis from the bioelectrical impedance analysis (bia) machine which will quantify fat, lean muscle, and water content; waist to hip ratio; handgrip strength; calf circumferences. socio-demographic data will also be collected. descriptive data analysis will take place to explore possible trends and associations which may inform future research and drive even further personalised care for this growing and typically underrepresented in research, population.


Eligibility criteria:
inclusion criteria: * adults eligible and accepting of assessment in the saop. 1. adults aged 70 years and over 2. a cancer diagnosis 3. just starting sact 4. able to provide at least 2 data sets during the study period (baseline + at least 1 research clinic visit) 5. willing and able to provide written informed consent exclusion criteria: * no further exclusions
solace trial - a phase 3 trial in subjects with non-infectious anterior-uveitis.

Conditions: Non-infectious Anterior Uveitis

Summary: a phase 3, randomized, double-masked, vehicle-controlled trial to evaluate the safety and efficacy of adx-102 ophthalmic solution in subjects with non-infectious anterior-uveitis.


Eligibility criteria:
inclusion criteria: * male or female subjects aged ≥ 18 years and ≤ 85 years. * subjects with acute non-infectious anterior uveitis with onset of symptoms within the previous 2 weeks. * best corrected visual acuity (bcva) better than or equal to 35 letters in the study eye and 65 letters in the non-study eye using etdrs testing. exclusion criteria: * have severe/serious ocular pathology in the study eye(s) which may preclude study completion, in the judgement of the investigator. * active intermediate or posterior uveitis in the study eye(s). * previous anterior uveitis episode in the study eye ≤ 4 weeks prior to screening. * have participated in another investigational device or drug study within 30 days prior to screening. * participation in a prior adx-102 study.

Keywords: reproxalap
the efficacy of gallium[68ga]nota-dna multivalent sgc8 injection for bladder tumour imaging

Conditions: Bladder Cancer

Summary: the study was planned to include patients with bladder tumors attending the department of urology, renji hospital, shanghai jiaotong university school of medicine, from 09/2024 to 12/2025. patient demographics will be collected, patients will be monitored for medical history and co-morbidities, co-morbid medications or treatments, vital signs, and cystoscopy will be performed. patients meeting the inclusion criteria will be included in this study. patients will receive pet/mr imaging after bladder instillation of \[68ga\] nota-dna multivalent sgc8 injection to assess the effectiveness of bladder tumor imaging and to evaluate the safety of \[68ga\] nota-dna multivalent sgc8. the primary study was the ability of gallium \[68ga\] nota-dna multivalent sgc8 injection to provide tumor-specific imaging of bladder tumor patients of different genders, with a compliance rate of more than 80% when compared to the gold standard tur pathology. to study the safety of gallium\[68ga\] nota-dna multivalent sgc8 injection; to assess the correlation between gallium\[68ga\] nota-dna multivalent sgc8 imaging ability and clinical parameters; to study the ability of gallium \[68ga\]nota-dna multivalent sgc8 to differentiate between bladder tumor foci and inflammatory foci; to explore the gallium \[68ga\]nota- dna multivalent sgc8 target ptk7 receptor protein expression in bladder tumors and the correlation between tumor differentiation and malignancy.


Eligibility criteria:
inclusion criteria: 1. voluntary enrolment with signed informed consent 2. age \>18 years, \<85 years 3. cystoscopic diagnosis of bladder tumour with imaging and pathology reports not required 4. willingness and ability to follow trial protocol requirements. exclusion criteria: 1. pregnancy, breastfeeding, severe hepatic, renal insufficiency and children 2. hypersensitivity to the test drug, allergy or allergy to multiple drugs
magnesium injection ensures steroid avoidance during vaccine, viremia or immunocompromise

Conditions: Steroid Metabolism Disorder

Summary: steroid injections are used for interventional pain management. however, their side-effect of immunosuppression may increase the risk of infections. magnesium is an alternative anti-nociceptive injection that may be used instead of steroids. prospective observational study of patients who received magnesium injection for interventional pain therapy, instead of steroid injection. post-injection data collection includes numerical rating pain score, and sleep quality score. pain is measured using the numeric pain rating scale. sleep score is measured using the likert sleep scale. a change in the pain or sleep scores by 2-points is considered significant.

corticosteroid injections are used for interventional pain management. the immunosuppression effect of steroid injection may increase the risk of infections. magnesium is an alternative anti-nociceptive agent that may be used for interventional pain injection therapy, instead of steroids. prospective observational clinical study of pain clinic patients who received magnesium injection for interventional pain therapy, instead of steroid injection. post-injection data collection includes numerical rating pain score, and sleep quality score. pain is measured using the numeric pain rating scale. sleep score is measured using the likert sleep scale. a change in the pain or sleep scores by 2-points is considered significant. data analyzed with ibm® spss® statistics 25 (ibm corp, armonk, ny); using student's t-test, anova, pearson chi-square test, and regression analysis. p-value \<0.05 is considered significant.

Eligibility criteria:
inclusion criteria: * adult chronic pain patients * previous interventional injection therapy * consent for interventional injection therapy * good treatment compliance * regular sleep diary * regular pain diary * informed consent for diary review * consent for clinical record quality assurance review exclusion criteria: * organ insufficiency * cognitive disorder * inability to provide consent * major neuropsychiatric disorder * unreliable diary * poor treatment compliance * previous adverse/allergic reactions to magnesium

Keywords: magnesium steroid avoidance
safety, efficacy and cost-effectiveness of racecadotril in children with acute diarrhea in mexico

Conditions: Diarrhea

Summary: rationale: acute diarrhea (ad) is still a significant morbidity-mortality problem worldwide. although oral rehydration therapy is the cornerstone, its anti-diarrheal effect is a controversial subject. since ten years ago, racecadotrilo´s safety and efficacy had been proved. however, a pharmacoeconomics analysis on this therapeutics has not been published yet. objective: evaluate the efficacy, safety, tolerability and costs associated with racecadotril administration in comparison to a placebo in infants up to 24 months of age with ad in a hospital (mildly or moderately dehydrated) and ambulatory (no dehydrated) settings at the national institute of pediatrics in mexico. material and methods: randomized, double-blind, placebo controlled, clinical trial (rdbcct) with pharmacoeconomics analysis (cost minimization) to realize in 454 infants with ad (270 hospitalized and 184 outpatients), 1 to 24 months of age who concomitantly will receive ort and racecadotril (1.5mg./kg./t.i.d. doe 5 days) (ort-rac group) or placebo (ort-placebo group). the clinical outcomes in the hospitalized infants to measure will be a) stool output rate at 48hs. and at the end of the study; b) duration of diarrhea; c) percentage of intravenous (iv) needs and d) percentage of adverse events. the outcome variables in outpatient infants to measure will be a) total liquid and semi-liquid bowel movements during the study; b) duration of diarrhea and c) percentage of adverse events. the pharmacoeconomics analysis will involve a cost minimization analysis (cma). results will be analyzed through bi and multivariate analysis using stata 11.0 for mac, considering a p value \< 0.05 as significant. the pharmacoeconomics model will made through decisions trees using treage pro healthcare v 1.2.0, 2009.


Eligibility criteria:
inclusion criteria: * children ≥ 1 month of age and ≤ 24 months of age * acute diarrhea (defined as three or more watery or semi-watery bowel movements for at least one day lasting no more than 5 days before being admitted) * for in hospital group: mild or moderate dehydration * signed informed consent letter exclusion criteria: * previous use of oral antibiotics for more than 48 hours (during the two weeks before the trial * previous use of anti-diarrheal medication (e.g.: bismuth subsalicylate, adsorbents, loperamide, combinations) * chronic pathologies (e.g.: cardiopathies, nephropathies, chronic gastrointestinal pathologies, endocrinopathies)

Keywords: acute diarrhea acute diarrhea (three or more watery or semi-watery bowel movements for at least one day lasting no more than 5 days before being admitted)
vocal in assessment of endometrium in postmenopause

Conditions: Postmenopausal Bleeding

Summary: the unbalanced estrogen with no progesterone will lead to endometrial thickening .this thickening result in endometrial hyperplasia \& carcinoma and lead to irregular bleeding

recent advances in the screening and diagnosis of endometrial pathologies (eg,endometrial hyperplasia , endometrial carcinoma ,endometrial polyps and myomas ) are directed towards non invasive methods as transvaginal ultrasound with 3 d application using different softwares . one of the applications of 3d transvaginal ultrasonography is vocal technique ( virtual organ computer aided analysis ) that can measure volume especially in tissues with irregular borders and this technology is considered to be superior than the conventional 2 d ultrasound . .

Eligibility criteria:
inclusion criteria: -postmenopausal women who were complaining of post-menopausal vaginal bleeding. exclusion criteria: * women with hormone replacement therapy. * women showing intra-cavitary fluid collection at ultrasound examination * women with other gynecological lesions in the pelvis other than the uterus * previous diagnosis of endometrial pathology.
two doses of conjugated estrogen (premarin) in patients with androgen-independent prostate cancer

Conditions: Prostate Cancer

Summary: the purpose of this study is to see if premarin is useful against androgen-independent prostate cancer and to help understand how drugs such as premarin may work.

patients will be randomly assigned to one of two study groups (arm a or arm b). arm a will receive 1.25mg of premarin once daily and arm b will receive 1.25mg of premarin three times a day. patients will also receive coumadin daily to help prevent thromboembolic disease. after reviewing the first 30 patients on arm a, it was determined that arm a (low dose premarin) was not effective. arm a was then closed and patients on arm a were given the choice to switch to arm b. treatment will continue until there is evidence of disease progression or unacceptable side effects. every 4 weeks while receiving premarin, a physical exam and blood work will be performed. every 12 weeks a ct scan of the abdomen and pelvis and a bone scan will be performed. patients will also be encouraged to undergo standard preventative breast irradiation prior to starting premarin or up to 4 weeks after starting treatment.

Eligibility criteria:
inclusion criteria: * documented histologic evidence of prostate cancer. * progressive androgen-independent prostate cancer as defined by the prostate-specific antigen (psa) working group after conventional androgen deprivation and antiandrogen withdrawal. * psa \> 2ng/ml and serum testosterone of \< 50ng/ml * no history of thromboembolic disease within the prior year * ecog performance status of 0-2 * creatinine \< 2 x upper limit of normal * bilirubin \< 2 x upper limit of normal * ast \< 2 x upper limit of normal exclusion criteria: * unstable angina or change in anginal symptoms within the past 6 months. * prior therapy with estrogens or pc-specs. * concurrent megestrol acetate or steroid hormones * major surgery or radiation therapy within 4 weeks * strontium-89 or samarium-153 therapy within 8 weeks

Keywords: androgen-independent prostate cancer premarin conjugated estrogen
pharmacodynamic comparison of rosuvastatin versus atorvastatin on platelet reactivity in patients with coronary artery disease on dual antiplatelet therapy with new p2y12 inhibitors (trial granada)

Conditions: Coronary Artery Disease

Summary: statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. the purpose of this study is to evaluate pharmacodynamic effects of rosuvastatin and atorvastatin on platelet reactivity in patients with coronary artery disease undergone double antiplatelet therapy with new p2y12 inhibitors. this is a single-center, prospective, randomized, crossover study conducted in the department of heart and great vessels "attilio reale", sapienza university, rome, italy. all consecutive patients undergone ptca in our institution in the period between july 2013 and december 2013 will be eligible to be enrolled. patients will be offered to participate to the trial at time of 1-month post-angioplasty follow-up visit.patients receiving dual antiplatelet therapy (prasugrel 10 mg or brilique 90 mg x 2 plus aspirin 100 mg) after percutaneous coronary intervention. patients were randomly assigned to rosuvastatin (20 mg day) or atorvastatin (40 mg day) for 30 days. after 1-week wash-out period to avoid any carryover effect, cross-over was performed, and patients were switched to the other drug which was continued for 30 days. platelet function will be evaluated using a validated method: the verifynow system (accumetrics inc., san diego, ca), which is a point-of-care turbidimetry-based optical detection system that measures platelet-induced aggregation. platelet function will be measured with the verifynow p2y12 test at baseline and after 30 days from rosuvastatin or atorvastatin administration. platelet reactivity will be expressed in p2y12 reaction units (pru). pru values \>208 are suggestive of high platelet reactivity.

statin interference has been suggested among the mechanisms of reduction of the antiplatelet effect of clopidogrel. the purpose of this study is to evaluate pharmacodynamic effects of rosuvastatin and atorvastatin on platelet reactivity in patients with coronary artery disease undergone double antiplatelet therapy with new p2y12 inhibitors. this is a single-center, prospective, randomized, crossover study conducted in the department of heart and great vessels "attilio reale", sapienza university, rome, italy.

Eligibility criteria:
inclusion criteria: 1. angiographically-proven coronary artery disease; 2. able to understand and willing to sign the informed cf; 3. stable clinical condition; 4. treatment with dual antiplatelet therapy (with p2y12 inhibitors); exclusion criteria: 1. other drugs or medications that affect cyp mediated drug metabolism; 2. allergy or adverse reactions to administered drugs;